How Is Bleomycin Stored? Stability, Per the Label and Research

Bleomycin Is Handled in a Clinical Setting

Bleomycin is a prescription medicine given by specialists in a clinical setting such as a hospital ward, an oncology infusion unit, an interventional suite or a critical care area. The vial is received, stored, checked and prepared by hospital or clinic pharmacy staff, and administration is carried out by the treating specialist team. Storage of bleomycin is therefore an institutional pharmacy topic rather than a home storage topic, and every statement below describes what a source document says, not what any reader ought to do.

This page is for educational purposes only and is not medical advice; consult a licensed physician or the treating specialist team about any question involving bleomycin. Questions about whether bleomycin is appropriate, how it would be given, or how a particular product is stored in a particular facility are for the prescribing clinician; talk to your prescriber.

Which Source Says What

Storage statements about bleomycin come from two very different kinds of documents, and mixing them produces confusion. Approved product labeling, also called the prescribing information or summary of product characteristics, carries the storage and stability conditions that regulators have accepted for a specific manufactured product. Peer reviewed literature on bleomycin, by contrast, is dominated by pharmacology, oncology, interventional practice and laboratory models, together with formulation science that builds new carriers around the molecule. The verified literature cited on this page does not include a shelf life stability study of commercial bleomycin vials, and no such finding is claimed here.

What Product Labeling Describes for Unopened Vials

Bleomycin for injection is supplied as a sterile powder in a sealed vial. Labeling for marketed bleomycin products describes the unopened vial as a refrigerated item, with the storage range usually written as 2 to 8 degrees C, equivalent to 36 to 46 degrees F. Because several manufacturers produce bleomycin and because labeling differs between countries, the approved label that accompanies the particular vial is the authoritative source for that vial. Hospital pharmacies work from that document and from institutional policy.

Labeling also assigns an expiry date to the unopened vial. That date applies to the product kept within the stated conditions in its original carton. Labels generally direct that the product be kept in the original container until it is prepared, and the carton protects the contents from light during storage. Statements of this kind come from the label and are reproduced here as regulatory facts rather than as advice.

Temperature excursions

Pharmacy practice treats any departure from the labeled range as a quality question for the manufacturer or for the institution's quality unit, because the label does not grant permission for storage outside the stated range. Public facing documents do not publish excursion allowances for bleomycin, and no excursion limit is asserted on this page.

Light, Container and Physical Appearance

The original carton and the sealed glass vial are the container closure system that the approved stability data were generated around. Labeling language about keeping the product in its carton until use reflects that, and it also reflects the general pharmaceutical principle that light exposure and container changes are variables outside the approved data set. Visual inspection of parenteral products before use is a standard pharmacy and nursing step described in labeling for injectables generally, and it is carried out by the clinical team rather than by a patient.

In Use Stability: What Labeling Covers

Once a sterile powder has been brought into solution, the stability clock described in the label applies for a limited period, and that period depends on the diluent, the container, the storage temperature and whether the preparation was carried out under validated aseptic conditions. Those details sit in the sections of the prescribing information written for healthcare professionals, and in national compounding standards that govern hospital pharmacy practice. No preparation steps, diluents, volumes or in use time limits are reproduced here, because this page is educational and because those details are operational instructions for licensed staff.

In practice, the in use period matters most to pharmacy workflow: batching, transport between pharmacy and ward, and the window during which a prepared syringe or bag remains acceptable. Institutional policy, the approved label and national standards together define that window.

What the Published Literature Adds on Bleomycin Formulations

Formulation research gives an indirect window onto bleomycin handling, because every new carrier has to address how the molecule behaves once it is encapsulated or mixed. The study by researchers who prepared bleomycin A2 loaded poly lactic co glycolic acid microspheres reported on the preparation of those microspheres together with related in vitro and in vivo studies, which is a formulation and delivery investigation rather than an assessment of commercial vial shelf life (PMID 21344412). Work of this type is investigational; such microsphere preparations are not approved products.

Admixtures prepared at the point of care also appear in the interventional literature. Researchers reported interim results of bleomycin polidocanol foam sclerotherapy described as a highly efficient technique for venous malformations, a procedure in which the agent is combined immediately before an image guided procedure by the specialist team (PMID 32284311). Use of bleomycin in venous malformations is investigational relative to approved oncology labeling, and the published report describes a specialist procedure, not a preparation that could be carried out elsewhere.

Inhaled carrier systems have been studied in the bleomycin lung injury model rather than as bleomycin formulations. The study describing an inhalation lenalidomide loaded liposome reported that the formulation was evaluated for improvement of bleomycin induced pulmonary fibrosis, meaning bleomycin served as the agent that created the disease model while lenalidomide was the encapsulated drug (PMID 37973629). That distinction matters when reading storage related claims, because stability work in such papers concerns the investigational carrier, not the bleomycin vial.

Bleomycin in Laboratory Models: What Studies Report

Much of the modern bleomycin literature uses the compound as a laboratory tool. Researchers reported that reactive oxygen species mediated lysosomal membrane permeabilization and autophagy inhibition regulated bleomycin induced cellular senescence (PMID 38762757). A separate study reported that PLAC8 attenuated pulmonary fibrosis and inhibited apoptosis of alveolar epithelial cells by facilitating autophagy in a bleomycin based fibrosis model (PMID 39810019). Another group reported that S1PR1 was a viable drug target against pulmonary fibrosis by increasing the integrity of the endothelial barrier of the lung (PMID 36970190). Investigators also reported that HDAC11 mediated deacetylation of triosephosphate isomerase 1 promoted idiopathic pulmonary fibrosis (PMID 41112094), and a nanomedicine study reported double braking effects on the mitochondrial permeability transition pore as a strategy for treating idiopathic pulmonary fibrosis (PMID 39475000). These reports concern pulmonary fibrosis biology in experimental systems and say nothing about how a clinical vial should be stored.

Approved Indications, at Label Level

Approved labeling for bleomycin products in the United States describes use in certain squamous cell carcinomas, in Hodgkin lymphoma and non Hodgkin lymphoma, in testicular carcinoma, and as a sclerosing agent for malignant pleural effusion. The exact wording and the list of indications vary by country and by product. Other uses discussed in the literature are investigational. A systematic review of topical treatment for plantar warts examined the published evidence base for agents applied in dermatology practice, including intralesional approaches (PMID 33263934), and the venous malformation report noted above sits in the same investigational category (PMID 32284311). Nothing on this page should be read as encouragement of any use outside approved labeling; whether a given indication applies is a decision for the prescribing clinician.

How This Differs From General Peptide Storage Topics

Bleomycin is a glycopeptide antibiotic family product supplied as a licensed sterile injectable, so its storage conditions are set by an approved label and enforced through pharmacy practice. General principles that circulate about peptide handling, such as cold chain, lyophilised versus solution state, light exposure and container choice, are summarised separately in the PeptideU guide at how to store peptides. Those general principles are useful background for understanding why labels specify refrigeration and limited in use windows, but they do not override or substitute for the approved label of a specific medicine, and they do not apply to a prescription chemotherapy product handled by hospital staff.

Degradation and Quality Questions: What Studies Report

The verified literature cited here does not include a forced degradation or long term stability study of marketed bleomycin vials, so no degradation pathway, impurity profile or shelf life figure is claimed. What the literature does show is sustained interest in controlling where and for how long bleomycin acts, which is the premise of the microsphere work that researchers reported on bleomycin A2 loaded particles together with in vitro and in vivo evaluation (PMID 21344412). Adjacent work on targeted RNA degradation as a therapeutic strategy illustrates how reviewers framed nucleic acid directed approaches in the broader field (PMID 41226803). Questions about the quality, appearance or expiry status of a particular vial are answered by the dispensing pharmacy and the treating specialist team.

Questions the Treating Specialist Team Can Answer

• Which approved product label applies to the vial being used, and what storage range does it state
• How the pharmacy documents refrigeration and handles any temperature excursion
• What in use period the label and institutional policy allow after preparation
• How the facility handles transport between pharmacy and the clinical area
• Whether the proposed use falls within approved labeling or is investigational

Each of these is a question for the prescribing clinician, the hospital pharmacist or the treating specialist team rather than something determined from a summary page.

References

• Preparation of bleomycin A2-PLGA microspheres and related in vitro and in vivo studies (Journal of Pharmaceutical Sciences, 2011)
• Interim results of bleomycin-polidocanol foam sclerotherapy as a highly efficient technique for venous malformations (Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2020)
• Topical treatment for plantar warts: A systematic review (Dermatologic Therapy, 2021)
• Inhalation Lenalidomide-Loaded Liposome for Bleomycin-Induced Pulmonary Fibrosis Improvement (AAPS PharmSciTech, 2023)
• ROS-mediated lysosomal membrane permeabilization and autophagy inhibition regulate bleomycin-induced cellular senescence (Autophagy, 2024)
• PLAC8 attenuates pulmonary fibrosis and inhibits apoptosis of alveolar epithelial cells via facilitating autophagy (Communications Biology, 2025)
• S1PR1 serves as a viable drug target against pulmonary fibrosis by increasing the integrity of the endothelial barrier of the lung (Acta Pharmaceutica Sinica B, 2023)
• HDAC11-Mediated Deacetylation of Triosephosphate Isomerase 1 Promotes Idiopathic Pulmonary Fibrosis (Research, 2025)
• Double Braking Effects of Nanomedicine on Mitochondrial Permeability Transition Pore for Treating Idiopathic Pulmonary Fibrosis (Advanced Science, 2024)
• Targeted RNA Degradation as a Promising Therapeutic Strategy (International Journal of Molecular Sciences, 2025)